CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Paclitaxel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00580983
NCT00580983N/ACompleted

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

University of Michigan Rogel Cancer Center·interventional·Posted Dec 27, 2007·Updated Sep 7, 2016

In Brief

A clinical study evaluating IMRT, Paclitaxel, and 3 other interventions for Head and Neck Cancer. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standard radiation methods. In order to reduce these side effects, other normal tissues may receive a different radiation dose (sometimes more) than what would have been received using standard radiation therapy. A secondary goal of this study is to determine if the type of tumor a patient has can be controlled at least as well (or better) using this advanced radiation therapy delivery technique as it would be if the patient was treated with standard radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 27, 2007
Enrollment StartAug 1, 2003
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.5 years ago

Interventions

IMRTradiation

Paclitaxeldrug

Carboplatindrug

Cisplatindrug

5-Fluorouracildrug